Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
Charles River Laboratories International, Inc. reported that EVP & Chief People Officer Victoria L. Creamer exercised stock options for 4,179 shares of common stock on 2026-08-06 at an exercise price of $179.66 per share and immediately sold 4,179 shares of common stock at $259.16 per share. The exercised options covered 4,179 shares and now show 0 derivative shares remaining from this grant.
CRL reporting person James Foster filed a notice of proposed sale of common stock. The filing lists a planned sale of 28,733 shares, to be acquired through the exercise of stock options for cash on 08/10/2026. Issuer common shares outstanding are shown as 47,738,872. Over the prior three months, Foster sold 75,000 shares of common stock for an aggregate value of $16,875,000.00.
Charles River Laboratories International, Inc. executive Shannon M. Parisotto, CEVP of Discovery & Safety Assessment, reported a sale of 5,046 shares of common stock at $263.00 per share on August 5, 2026, under a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following the sale, Parisotto directly holds 4,807 shares, and also reports indirect ownership of 9,680 shares held by a trust and 28,510 shares held through Karpathos Investments LLC.
Charles River Laboratories International, Inc. has a planned sale of common stock under Rule 144. The planned sale involves 4,300 shares underlying RSUs and PSUs granted on 01/28/2022 and 2,345 shares from a stock option exercise. The anticipated sale date is 08/06/2026, with transactions routed through UBS Financial Services Inc. and listed on the NYSE.
FMR LLC reports beneficial ownership of 4,239,751.47 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. common stock, representing 8.8% of the class as of June 30, 2026. FMR has sole voting power over 4,190,715.80 shares and sole dispositive power over 4,239,751.47 shares, with no shared voting or dispositive power.
Abigail P. Johnson is reported with sole dispositive power over the same 4,239,751.47 shares but no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no single person holds more than five percent of the outstanding common stock. Subsidiary details are referenced in an attached exhibit.
CRL has a Form 144 notice indicating a potential sale of up to 5,046 shares of common stock on the NYSE, with an aggregate market value of $1,327,098.00. The filing lists total common shares outstanding of 47,738,872. The sale, proposed for 08/05/2026, includes shares from performance stock awards granted on 01/27/2023 (3,511 shares) and 01/29/2024 (1,535 shares) by the issuer.
Charles River Laboratories International, Inc. reported second‑quarter 2026 revenue of $1.00 billion, down 2.7% from $1.03 billion a year earlier, while organic revenue edged up 0.1%. GAAP results swung to a small net loss of $(1.5) million, or $(0.03) per share, primarily due to a $63.7 million loss on the divestiture of its CDMO and Cell Solutions businesses.
On a non‑GAAP basis, operating margin was 20.5% versus 22.1% and net income declined 5.0% to $146.2 million, with diluted EPS of $3.02 compared with $3.12 in the prior‑year quarter. Segment results were mixed: RMS revenue was $209.5 million with organic revenue down 1.4%, DSA revenue was $606.5 million with organic growth of 0.2%, and Manufacturing revenue was $188.1 million, down 6.3% reported but up 1.3% organically.
The company repurchased $100.0 million of stock in the quarter and $300.0 million year‑to‑date, leaving $700.0 million under its $1.0 billion authorization. For 2026, it raised organic revenue growth guidance to 0.0%–1.0% and non‑GAAP EPS to $11.15–$11.45, while lowering GAAP EPS guidance to $3.05–$3.35 to incorporate divestiture‑related losses.
Charles River Laboratories director James C. Foster reported an open-market sale of 75,000 shares of common stock at $225.00 per share. The sale was executed pursuant to a Rule 10b5-1 Trading Plan adopted on March 6, 2026. After the sale, he holds 31,596 shares directly and additional indirect holdings through various trusts and GRATs.